Y
Yingchun Hou
Researcher at Shaanxi Normal University
Publications - 37
Citations - 748
Yingchun Hou is an academic researcher from Shaanxi Normal University. The author has contributed to research in topics: Cancer & Peptide library. The author has an hindex of 10, co-authored 31 publications receiving 468 citations.
Papers
More filters
Journal ArticleDOI
Cancer stem cell targeted therapy: progress amid controversies
Tao Wang,Tao Wang,Sarah Shigdar,Michael P. Gantier,Michael P. Gantier,Yingchun Hou,Li Wang,Yong Li,Hadi Al. Shamaileh,Wang Yin,Shu-Feng Zhou,Xinhan Zhao,Wei Duan +12 more
TL;DR: The current status and progresses of cancer stem cells theory is illustrated and via providing a panoramic view of cancer therapy, the recent controversies regarding the feasibility of cancerstem cells targeted anti-cancer therapy are addressed.
Journal ArticleDOI
Exosomes and Nanoengineering: A Match Made for Precision Therapeutics.
Phuong H.L. Tran,Dongxi Xiang,Thao T.D. Tran,Wang Yin,Yumei Zhang,Lingxue Kong,Kuisheng Chen,Miaomiao Sun,Yong Li,Yingchun Hou,Yimin Zhu,Wei Duan +11 more
TL;DR: Recent advances in targeted exosomal delivery systems engineered by aptamer for future strategies to promote human health using this class of human‐derived nanovesicles are summarized.
Journal ArticleDOI
Challenges and opportunities for siRNA-based cancer treatment.
Tao Wang,Tao Wang,Sarah Shigdar,Hadi Al. Shamaileh,Michael P. Gantier,Michael P. Gantier,Wang Yin,Dongxi Xiang,Lan Wang,Shu-Feng Zhou,Yingchun Hou,Peng Wang,Weihong Zhang,Chunwen Pu,Wei Duan +14 more
TL;DR: Key challenges facing siRNA-based cancer treatment are discussed from recent clinical and preclinical studies, including chemical modification, tumour penetration, endosomal escape, target selection and off-target effects.
Journal ArticleDOI
Transforming doxorubicin into a cancer stem cell killer via EpCAM aptamer-mediated delivery.
Dongxi Xiang,Sarah Shigdar,Andrew G. D. Bean,Matthew Bruce,Wenrong Yang,Motilal Mathesh,Tao Wang,Tao Wang,Wang Yin,Phuong H.L. Tran,Hadi Al. Shamaileh,Roberto A. Barrero,Pei Zhuo Zhang,Yong Li,Lingxue Kong,Ke Liu,Shu-Feng Zhou,Yingchun Hou,Aina He,Wei Duan +19 more
TL;DR: The data demonstrate that a CSC-targeting aptamer is able to transform a conventional chemotherapeutic agent into a C SC-killer to overcome drug resistance in solid tumours.
Journal ArticleDOI
Aptamer-guided extracellular vesicle theranostics in oncology
Phuong H-L Tran,Dongxi Xiang,Tuong Ngoc-Gia Nguyen,Thao T D Tran,Qian Chen,Wang Yin,Yumei Zhang,Lingxue Kong,Andrew Duan,Kuisheng Chen,Miomio Sun,Yong Li,Yingchun Hou,Yimin Zhu,Yongchao Ma,Guoqin Jiang,Wei Duan +16 more
TL;DR: A current picture of the research on exosomes and aptamers and their applications in cancer theranostics is provided, highlighting recent advances in their transition from the bench to the clinic.